@article{43fdf78c6018442abe2767272f63fbb4,
title = "Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials",
keywords = "Cholangiocarcinoma, Biliary tract cancer, Adjuvant therapy, Neoadjuvant therapy, Chemotherapy, Chemoradiotherapy, PERIHILAR CHOLANGIOCARCINOMA, GEMCITABINE CHEMOTHERAPY, GALLBLADDER CARCINOMA, PROGNOSTIC-FACTORS, PLUS GEMCITABINE, RESECTION, CISPLATIN, SURVIVAL, S-1, OXALIPLATIN",
author = "A. Belkouz and Wilmink, {J. W.} and Mohammad, {N. Haj} and J. Hagendoorn and {de Vos-Geelen}, J. and Dejong, {C. H. C.} and Homs, {M. Y. V.} and Koerkamp, {B. Groot} and {van Gulik}, {T. M.} and {van Oijen}, {M. G. H.} and Punt, {C. J. A.} and H. Klumpen",
year = "2020",
month = jul,
doi = "10.1016/j.critrevonc.2020.102975",
language = "English",
volume = "151",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Science",
}